California
Anaheim; Advanced Clinical Research Institute
Hepatitis C research study for Latino and non-Latino patients who are treatment Naïve.
Palo Alto; Stanford University School of Medicine
Randomized, Multicenter, Open Label, Phase IV Study Evaluating the Efficacy and Safety of 16-Week Versus 24-Week Treatment with PEGASYS in Combination with Copegus in Interferon-naïve Patients with Chronic Hepatitis C Genotype 2 or 3 Virus Infection
Maryland
Laurel; Maryland Digestive Disease Research, LLC
Hepatitis B for naïve patients
New Jersey
Egg Harbor Township; AGA Clinical Research Associates, LLC
Hepatitis C Infection
New York
Manhasset; Biomedical Research Alliance of New York
Treatment Naïve Subjects with Genotype 1 Chronic Hepatitis C - Adults
Manhasset; Biomedical Research Alliance of New York
People with chronic hepatitis B are asked to participate in a research study being conducted by North Shore University Hospital.
New York; Mount Sinai Medical Center
Comparison of Peg-Intron 1.5 ug/kg/wk Plus Rebetol vs. Peg-Intron 1 ug/kg/wk Plus Rebetol vs. Pegasys 180 ug/wk Plus Copegus in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1 [P03471]
New York; Mount Sinai Medical Center
A Prospective, Multicenter, Open-Label, Comparative, Efficacy Study of Pegasys plus Copegus in Treatment-Naive Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naive Non-Latino Caucasian Patients with Chronic Hepatitis C-Genotype 1 (ML18179)
New York; Mount Sinai Medical Center
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B [GS-US-174-0102]
New York; Biomedical Research Alliance of New York
Chronic Hepatitis C- Non-Responsive to Prior Interferon Alfa Treatment
New York; Biomedical Research Alliance of New York
Chronic Hepatitis C- Non-Responsive to Interferon Alfa Treatment
New York; Biomedical Research Alliance of New York
Chronic Hepatitis C-Non-Responsive to Interferon Alfa Treatment
International
Cagliari, Italy; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis D (CHD)
Bucharest, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)
Cluj-Napoca, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)
Constanta, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)
Craiova, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)
Iasi, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)
Timisoara, Romania; Research Site:
A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis D (CHD)
